Attention Bias Modification (ABM) for Major Depressive Disorder
Completed
- Conditions
- Major Depressive Disorder (MDD)
- Registration Number
- NL-OMON24957
- Lead Sponsor
- Pro Persona, Center for Mental Health Care, Nijmegen, The NetherlandsWolfheze 2, 6874 Wolfheze
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 126
Inclusion Criteria
•A diagnosis of major depressive disorder, first or recurrent according to the DSM- IV-TR, as assessed with the MINI Neuropsychiatric Interview
•Age: between 18-65 years
Exclusion Criteria
•Any psychotic disorder (current or previous)
•Current mania or hypomania or a history of bipolar disorder
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method •Attentional bias (dot-probe task)<br /><br>•Depression level as assessed by the Inventory of Depressive Symptomatology self-report (IDS-SR)<br /><br>•Emotional vulnerability in response to a speech task as measured by the Spielberger State Anxiety Inventory (STAI-S) and the Positive and Negative Affect Scale (PANAS)<br>
- Secondary Outcome Measures
Name Time Method •Attentional control, as measured by the classical Stroop task <br /><br>•Attentional bias for verbal positive and negative information (‘emotional Stroop task’), <br /><br>•Ruminative Response Scale (RRS-NL) <br /><br>•Positive and Negative Affect (PANAS)<br /><br>•Prospective Imagery Task (PIT) <br /><br>•Resilience Scale (RS) <br /><br>•Number of sessions of out-patient therapy needed <br /><br>•Credibility/Expectancy Questionnaire (CEQ) <br /><br>•Quality of life (EuroQol; EQ-5D) and costs/ health care utilization (Trimbos/iMTA questionnaire; TicP) <br /><br>•Diagnostic status of depression according to the DSM-IV-TR as assessed by the MINI Neuropsychiatric Interview
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What neural mechanisms underlie ABM's efficacy in treating Major Depressive Disorder (MDD)?
How does ABM compare to SSRIs and CBT in reducing rumination and cognitive reactivity in MDD patients?
Which biomarkers, such as resting-state fMRI or cortisol levels, predict response to ABM in MDD?
What adverse events are associated with ABM protocols in MDD clinical trials, and how are they managed?
How do ABM interventions integrate with digital therapeutics or neurofeedback for MDD treatment optimization?